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disease in an immunocompromised 
patient. However, most cases of M. 
fortuitum pneumonia were reported 
before the use of molecular technology 
for species identiﬁ  cation.  Newer 
species such as M. mageritense 
resemble M. fortuitum and would not 
have been differentiated without this 
method.
Our patient met the criteria 
for diagnosing nontuberculous 
mycobacterial lung disease as 
established by the American 
Thoracic Society and the Infectious 
Diseases Society of America (9). Her 
therapeutic response also supports a 
cause-and-effect relationship.
The identity of an RGM isolate 
as M. mageritense may be suspected 
by its unusual antimicrobial drug 
susceptibility pattern, which showed 
an intermediate MIC to amikacin 
and resistance to clarithromycin at 
3 days (Table). However, deﬁ  nitive 
identiﬁ   cation requires molecular 
methods. Previous studies have 
shown that M. mageritense contains 
an inducible erythromycin methylase 
gene (erm 40) that confers macrolide 
resistance (10). The use of molecular 
studies and greater attention to 
susceptibility patterns should 
enable increased recognition of M. 
mageritense as a human pathogen. 
We thank Steven McNulty, Linda 
Bridge, and Ravikiran Vasireddy for 
laboratory assistance and Joanne Woodring 
for typing the manuscript.
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Extensively 
Drug-Resistant 
Tuberculosis, China 
To the Editor: The prevalence 
of drug-resistant tuberculosis (TB) 
is a serious problem in the People’s 
Republic of China. China is 1 of 22 
countries with the highest incidence 
of TB (1). It is also 1 of 27 countries 
with the highest incidence of 
multidrug-resistant TB (MDR TB) 
and extensively drug-resistant TB 
(XDR TB). According to the national 
baseline survey on TB in 2007 and 
2008, the frequency of MDR TB 
among pulmonary TB patients in 
China was 8.3%. We estimate that 
there are 120,000 new cases of MDR 
TB in China per year, which accounts 
for 24.0% of new cases worldwide 
(510,000) per year.
XDR TB has recently emerged as 
a global public health problem (2). It is 
deﬁ  ned as TB with resistance to at least 
isoniazid, rifampin, a ﬂ  uoroquinolone, 
and 1 of 3 injectable second-line drugs 
(amikacin, kanamycin, or capreo-
mycin). XDR TB is a type of MDR 
TB that shows resistance to isoniazid 
and rifampin. Recent reports on current 
prevalence of XDR TB (3,4) indicate 
that China now has the second highest 
incidence of MDR TB worldwide. 
However, there is no information 
available on XDR TB in China.
To obtain information on XDR 
TB in China, we conducted a study 
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at Shanghai Pulmonary Hospital. It 
is the only specialized hospital for 
TB in Shanghai and plays a major 
role in treating TB patients and 
providing state-of- the-art treatment. 
Most patients referred to this hospital 
have been previously treated or have 
recurrent TB. Therefore, higher rates 
of MDR TB and XDR TB are expected 
in this setting, which is not comparable 
to community or multicenter-based 
studies.
Patients with culture-proven 
MDR TB during January 2008–June 
2009 were retrospectively evaluated. 
All patients were HIV negative. Drug 
susceptibility testing was conducted 
for culture-positive isolates by using 
the BACTEC 960 System (Becton 
Dickinson, Franklin Lakes, NJ, USA) 
at concentrations of 0.1 μg/mL for 
isoniazid, 1 μg/mL for rifampin, 
5  μg/mL for ethambutol, 1 μg/mL 
for streptomycin, 2.5 μg/mL for 
capreomycin, 1μg/mL for amikacin, 
and 2 μg/mL for oﬂ  oxacin.
Among 518 strains that were 
culture positive for Mycobacterium 
tuberculosis, 350 (67.6%) were drug 
resistant and 168 (32.4%) were drug 
sensitive. A total of 217 (41.9%) of 
518 strains were classiﬁ   ed as MDR 
and accounted for 62.0% of drug-
resistant strains. Among 217 MDR 
strains, 45 (20.7%) were from patients 
who had a new diagnosis of TB, and 
172 (79.3%) were from patients whose 
medical history included treatment 
for TB for >4 weeks. A total of 65 
(12.6%) strains were XDR, of which 
51 were from patients previously 
treated. These strains accounted for 
18.6% of drug-resistant strains and 
30.0% of MDR strains.
Of 217 MDR isolates, 217 
(100.0%), 217 (100.0%), 172 
(79.3%), 175 (80.6%), 170 (78.3%), 
68 (31.3%), and 69 (31.8%) were 
resistant to isoniazid, rifampicin, 
streptomycin, ethambutol, oﬂ  oxacin, 
capreomycin, and amikacin, 
respectively. Of 65 XDR isolates, 65 
(100.0%), 65 (100.0%), 61 (93.9%), 
60 (92.3%), 65 (100.0%), 60 (92.3%), 
and 60 (92.3%) were resistant to 
isoniazid, rifampicin, streptomycin, 
ethambutol, oﬂ  oxacin,  capreomycin, 
and amikacin, respectively.
Our results indicate that 30.0% 
of MDR strains were XDR strains. 
Although our study was conducted 
in only 1 hospital, this prevalence of 
XDR strains indicates that XDR TB in 
China is a serious concern. A total of 
78.3% of MDR isolates were resistant 
to oﬂ  oxacin, which is higher than rates 
reported for South Korea (42.8%) (5) 
and Taiwan (16.6%) (6). Population-
based studies have reported lower 
frequencies of XDR strains among 
MDR strains; 9.9% for 14 qualiﬁ  ed 
reference laboratories (7), 5.3% for 
South Korea (8), and 23.9% for South 
Africa among patients co-infected 
with HIV and TB (9).
In our study, 2 factors may have 
contributed to high drug-resistance 
rates. First, ﬂ  uoroquinolones  have 
been widely used for treatment of 
respiratory tract bacterial infections 
because of their efﬁ   cacy and mild 
adverse reactions. Second, we also 
prescribed  ﬂ  uoroquinolones  for 
treatment of patients with drug-
resistant TB and some patients with 
drug-sensitive TB who could not 
tolerate ﬁ  rst-line anti-TB drugs. More 
than 90% of patients with XDR TB 
had strains resistant to streptomycin, 
ethambutol, capreomycin, and 
amikacin, which was higher than rates 
reported in other studies (5,9,10). 
Currently, anti-TB medications in 
China for treatment of patients with 
XDR TB are scarce. This scarcity has 
resulted in poor treatment outcomes in 
patients with XDR TB.
One limitation of our study is 
that we investigated patients at only 1 
specialized TB hospital in Shanghai. 
Therefore, data are not representative 
for the general population. A 
community-based multicenter study 
is needed to determine the true 
prevalence of XDR TB in China. 
Nevertheless, our study conﬁ  rms 
that the prevalence of MDR TB and 
XDR TB is high in some areas. It 
also emphasizes the need to increase 
TB prevention and therapy, educate 
society about TB, implement modern 
TB control strategies, and strengthen 
basic and clinical research to curb the 
spread of MDR TB and XDR TB.
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Clade 2.3.2 Avian 
Inﬂ  uenza Virus 
(H5N1), Qinghai 
Lake Region, China, 
2009–2010 
To the Editor: In 2005, a large 
population of wild migratory birds 
was infected with highly pathogenic 
avian inﬂ  uenza (HPAI) virus (H5N1) 
in the Qinghai Lake region of western 
People’s Republic of China, resulting 
in the death of ≈10,000 birds (1,2). On 
the basis of phylogenetic analysis of 
the hemagglutinin (HA) gene, the virus 
was classiﬁ  ed as clade 2.2 according 
to the World Health Organization 
guidelines. Subsequently, viruses from 
this clade were found in Mongolia, 
Russia, Europe, and Africa along 
the migratory ﬂ  yways of birds (3,4). 
This unique distribution of the same 
clade of HPAI virus (H5N1) through 
different migratory routes indicates 
that migratory birds might play a global 
role in virus dissemination (3,4).
In 2006, viruses from the same 
clade were isolated in the Qinghai Lake 
region (3). Analysis of viral outbreaks 
along migratory ﬂ  yways demonstrated 
a similar outbreak pattern for the past 
4 years (2006–2009) (5). During that 
period, clade 2.2 avian inﬂ  uenza 
virus (H5N1) was isolated in China, 
Mongolia, Russia, Germany, Egypt, 
and Nigeria; all viruses were closely 
related to the Qinghai Lake virus. 
Despite the broad distribution of clade 
2.2 viruses in migratory ﬂ  yways, 
few isolates of clade 2.2 viruses in 
local domestic poultry were reported, 
especially in China (6). Outbreaks of 
these viruses were reported in poultry 
in Africa (7). The reason these viruses 
rarely cause outbreaks in poultry is 
unknown.
During May–June 2009 and 2010, 
several dead migratory birds were 
found in the Qinghai Lake region. Nine 
HPAI viruses (H5N1) were isolated 
in 2009 and 2 were isolated in 2010 
from great cormorants (Phalacrocorax 
carbo), brown-headed gulls (Chroico-
cephalus brunnicephalus), great black-
headed gulls (Ichthyaetus ichthyaetus), 
great-crested grebes (Podiceps 
cristatus), and bar-headed geese (Anser 
indicus) and serotyped as described 
(3). HA genes from all 11 isolates 
were subsequently ampliﬁ  ed  by 
using reverse transcription–PCR and 
sequenced.
Phylogenetic analysis of HA 
sequences and an additional HA gene 
sequence from the 2009 Qinghai Lake 
subtype H5N1 virus isolate from a 
great crested grebe (from the National 
Avian Inﬂ  uenza  Virus  Reference 
Laboratory, Harbin, China) (GenBank 
accession no. CY063318) showed 
that HA genes from all 12 viruses 
clustered as clade 2.3.2 (Figure); 
none clustered with clade 2.2 viruses. 
Additionally, the HA cleavage site in 
the new isolates is PQRERRRKRG, 
which is identical to that of clade 2.3.2 
viruses. In clade 2.2, the cleavage site 
is PQRERRRKKRG.
A bootstrap (1,000×) maximum 
likelihood tree (8) also demonstrated 
that Qinghai 2009 and 2010 virus 
isolates are closely related to those 
isolated in Mongolia and Uvs Nuur 
Lake in 2009, as reported by Sharshov 
et al. (5). Qinghai Lake and Uvs Nuur 
Lake, which are found along the 
migratory ﬂ  yway in central Asia, are 
major lakes for bird migration and 
breeding. Many birds ﬂ  y from Qinghai 
Lake to Uvs Nuur Lake in the spring.
If one considers isolation date and 
bird species infected, viruses isolated in 
Mongolia and Russia and our isolates 
were likely transmitted between the 
2 lake regions by bird migration. 
Moreover, HA sequences are closely 
related to viruses isolated from wild 
birds in Hong Kong and Japan during 
2007–2008, which are the most 
recent isolates of clade 2.3.2 viruses 
before isolation of 2009 Qinghai Lake 
viruses. These results indicate that 
viruses in the Qinghai Lake region 
may be transmitted by wild birds 
along the migratory ﬂ  yway in eastern 
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